At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 296 enrolled
Drug / intervention
Topiramatedrug
Likely dose
Topiramate 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Continuous Treatment Study of JNS019 (Topiramate) in Migraine Patients
In Brief
A Phase 2 clinical trial evaluating Topiramate for Migraine. Completed, enrolled 296 participants across 25 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of topiramate in participants with migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting and constipation or diarrhea) who completed the JNS019-JPN-02 study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
Primary CompletionNov 2009
First PostedFeb 2013
TodayJul 2026
First PostedFeb 27, 2013
Enrollment StartAug 1, 2007
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.3 years ago
Interventions
Topiramatedrug
Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.